Ratings Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse Other stock markets 04:00:02 2024-06-07 pm EDT			5-day change	1st Jan Change
20.75 ^USD	+0.39%		-2.72%	+43.90%

May. 24	Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation	MT
May. 24	Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14	CI

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The company is one of the best yield companies with high dividend expectations.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
One of the major weak points of the company is its financial situation.
The company appears highly valued given the size of its balance sheet.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ORGANON & CO.	+43.90%	5.32B	B
ELI LILLY AND COMPANY	+45.82%	754B	C+
NOVO NORDISK A/S	+40.95%	630B	B
JOHNSON & JOHNSON	-6.16%	352B	C+
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	298B	C+
ASTRAZENECA PLC	+18.45%	250B	B+
NOVARTIS AG	+11.88%	217B	B-
ROCHE HOLDING AG	-0.78%	216B	A+
AMGEN INC.	+5.90%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes